髓外浆细胞瘤的诊断与鉴别诊断

目的 探讨髓外浆细胞瘤(ExtrameduUary plasmacytoma,EMP)的诊断和鉴别诊断.方法 对16例EMP的组织形态学及免疫表型特征进行研究,并与3例髓外多发性骨髓瘤(Extramedullary multiple myeloma,EMM)、3例髓内多发性骨髓瘤(medullary multiple myeloma,MM)及10例浆细胞反应性增生作比较.结果 16例EMP,Ⅰ级2例,Ⅱ级12例(富浆型9例,少浆型3例),Ⅲ级2例.3例EMM为Ⅱ级少浆及富浆型各1例,Ⅲ级1例;3例MM均为Ⅱ级(富浆型2例,少浆型1例).10例浆细胞反应性增生均为成熟浆细胞,常混有淋巴细胞和组织细胞.免疫组化显示16例EMP均呈轻链限制性,CD20、CD56及CyclinD1均阴性;CD138 62.5%(10/16)阳性,Bcl-2 37.5%(6/16)阳性,但均强度较弱;CD79a 71.4%(10/14)阳性,LCA 42.8%(6/14)阳性,EMA28.5%(2/7)阳性.3例EMM和MM均呈轻链限制性,CD138均阳性.CD56阳性4例(含3例EMM),Bcl-2阳性5例(含3例EMM),均强阳性.10例浆细胞反应性增生均无轻链限制性.结论 Ⅰ级EMP应与浆细胞反应性增生相鉴别;Ⅱ级者应与小B细胞淋巴瘤、粒细胞肉瘤及浆细胞样肌上皮瘤相鉴别;Ⅲ级者应与大细胞性淋巴瘤、恶性黑色素瘤、低分化癌、肌源性肉瘤及肾外横纹肌样瘤相鉴别.CD56和Bcl-2可能是鉴别EMP和EMM的有用标记.     

腹壁髓外浆细胞瘤1例报告

浆细胞肿瘤是单克隆性浆细胞异常增殖性疾病。按照WHO分类,浆细胞肿瘤被分为浆细胞骨髓瘤〔多发性骨髓瘤(MM)〕、骨孤立性浆细胞瘤(solitary plasmacytomaofbone,SPB)和髓外浆细胞瘤(extramerdullary plasmacytoma,EMP)。EMP占全部浆细胞肿瘤的5%～10%。其中约80%的EMP发生于上呼吸道,胃肠道约占10%,发生于腹部皮下的EMP报道较少。本研究将确诊的1例EMP病例报道如下。     

子宫间变型浆细胞瘤1例报道

0 引言 浆细胞瘤( plasmacytoma)是包括多发性骨髓瘤(mutiple myeloma,MM)、骨孤立性浆细胞瘤(solitaryplasmacytoma of bone,SPB)、髓外浆细胞瘤( extramedullary plasmacytoma,EMP)及浆细胞性白血病(Plasma cellleukemia,PCL)的一组疾病.其中EMP是指原发于骨髓造血组织以外的浆细胞肿瘤,是恶性单克隆浆细胞病变中较为罕见的一种,且因缺乏典型的临床特征,致使确诊相对困难[1],其发病率占所有浆细胞瘤的3％～5％,约80％发生于上呼吸道[2-3],常见于鼻腔、鼻咽、鼻旁窦、喉、会厌、扁桃体等.间变型EMP国内外仅见个别报道,而发生于子宫腔的间变型EMP则极为罕见.简阳市人民医院于2007年1月收治1例,现报道如下.     

50例孤立性浆细胞瘤临床分析

目的对孤立性浆细胞瘤(SP)的特点和预后因素进行回顾性分析,以帮助临床诊断、治疗及对预后的判断。方法入组50例SP患者,并对其进行随访,应用Kaplan-Meier法对其临床特点、治疗及预后因素进行回顾性分析。结果髓外浆细胞瘤(EMP)组与骨孤立性浆细胞瘤(SPB)组、放疗组与未放疗组、年龄﹤60岁与年龄≥60岁组的log rank检验结果提示,生存曲线差异均无统计学意义(P均>0.05)。50例SP患者与168例多发性骨髓瘤(MM)患者的生存曲线差异有统计学意义(P<0.05)。结论 SP患者中,EMP与SPB的生存状况无明显差异,SP好发于中老年人,预后较好,部分可转化为MM。     

淋系抗原表达对急性髓系白血病预后的价值

目的:探讨淋系抗原表达在急性髓系白血病（acute myeloid leukemia,AML）预后方面的临床意义。方法:应用流式细胞术检测我院101例初诊AML患者的免疫表型,以CD7-CD19-CD56-AML为对照组,将CD7+AML组、CD19+AML、CD56+AML组与对照组的临床特征、疗效进行分析比较,随访并观察生存曲线的差异。结果:101例AML患者中淋系抗原表达者52例(51.5%),CD7抗原表达29例（28.7%）,CD56抗原表达29例（28.7%）,CD19抗原表达13例（12.8%）;CD7+AML、CD19+AML、CD56+AML患者与对照组间的发病年龄、肝脾大、髓外浸润、白细胞计数、血红蛋白、骨髓原始细胞比例差异无统计学意义（P＞0.05）,CD7+AML组血小板计数偏低（P＜0.05）;CD56+AML组首次完全缓解率（CR）率及总CR率均低于对照组（P＜0.05）;CD7+AML、CD19+AML组首次CR率及总CR率与对照组相比差异均无统计学意义（P＞0.05）;与对照组相比,CD56+AML组无复发生存期（RFS）缩短（P＜0.05）,CD7+AML、CD19+AML组RFS与对照组差异无统计学意义（P＞0.05）。结论:CD56+AML患者常规化疗不敏感,疗效差,CD56抗原可能是AML患者的预后不良因素;CD7、CD19抗原不影响AML患者的预后。     

以咯血和左肾占位为首发症状的多发性骨髓瘤1例

髓外浆细胞瘤(extramedullary plasmacytoma,EMP)是指原发于骨髓造血组织以外的浆细胞肿瘤,为恶性单克隆浆细胞病变中较为罕见的一种(不足全身浆细胞瘤的4%)。EMP可发生于任何髓外组织或器官,但约80%发生于上呼吸道,常见于鼻腔、鼻窦、鼻咽部和口腔。多发性骨髓瘤(multiple myeloma,MM)亦是浆细胞恶性肿瘤,好发于中老年人,其发病率居血液系统恶性肿瘤的第二位,约占血液系统恶性肿瘤的10%。现将本院收治的1例以咯血和左肾占位为首发症状的MM的诊治经过报告如下。     

多参数流式细胞术对多发性骨髓瘤患者的诊断和预后预测价值

目的 研究多参数流式细胞术对多发性骨髓瘤(MM)患者的诊断和预后预测价值.方法 选取86例MM患者作为观察组,再选择同期自愿接受多参数流式细胞术检查的健康体检人群40例作为对照组.采用多参数流式细胞术检测两组受试人群免疫表型(CD19、CD117、CD56、CD138、CD38)异常克隆浆细胞表达情况,统计观察组总生存率及不同免疫表型阳性和阴性患者总生存率;使用受试者工作特征(ROC)曲线及曲线下面积(AUC)分析不同免疫表型对MM患者的预后预测价值,并以CD45/SS设门,分析不同组合[CD38(+)/CD138(+)/CD19(-)、CD38(+)/CD138(+)/CD19(-)/CD56(+)、CD38(+)/CD138(+)/CD19(-)/CD117(+)]对MM患者的预后预测价值.结果 两组受试者CD138阳性率比较,差异无统计学意义(P>0.05);观察组患者CD19阳性率明显低于对照组,CD117、CD56、CD38阳性率均明显高于对照组,差异均有统计学意义(P<0.01).ROC曲线分析结果显示,CD19、CD117、CD138、CD38免疫表型对MM患者的预后预测价值有限(AUC<0.6),CD56免疫表型对MM患者有一定的预后预测价值(AUC>0.6).不同组合对MM患者的预后预测价值均高于免疫表型(P<0.05),且CD38(+)/CD138(+)/CD19(-)的AUC最大,提示其预后预测价值最高.结论 多参数流式细胞术中免疫表型分析可为MM患者诊断提供一定参考价值,不同组合在预后预测中有较高的应用价值.     

ezrin与乳腺浸润性导管癌发生发展及预后的关系

目的 探讨ezrin蛋白在乳腺浸润性导管癌及导管内增生性病变中的表达及其临床病理意义.方法 采用免疫组织化学方法,检测临床病理及随访资料完整的88例乳腺浸润性导管癌和54例导管内增生性病变组织中ezrin的表达情况,分析其与CD44v6、E-cadherin表达的关系及其临床病理意义;采用Kaplan-Meier法和Cox回归模型分析ezrin表达与乳腺导管浸润癌患者预后的关系.结果免疫组化染色结果显示,在乳腺正常导管上皮、普通型导管增生、不典型导管增生和浸润性导管癌组织中,ezrin的强阳性表达率分别为9.1%、16.7%、43.3%和64.8%.ezrin在乳腺不典型导管增生和浸润性导管癌组织中的强阳性表达率明显高于乳腺普通型导管增生和正常导管上皮组织(P＜0.05),而在浸润性导管癌组织中的强阳性表达率亦明显高于不典型导管增生组织(P＜0.05).在乳腺浸润性导管癌组织中,ezrin强阳性表达率与腋窝淋巴结转移状况、组织学分级、TNM分期及CD44v6的表达呈正相关,与E-cadherin的表达呈负相关(P＜0.05).ezrin强阳性表达组患者的术后生存时间明显短于阴性组(P＜0.05).结论 ezrin可能在乳腺浸润性导管癌的发生、发展中发挥重要作用,ezrin强阳性表达提示乳腺浸润性导管癌患者的预后较差.     

脊柱浆细胞骨髓瘤中骨桥蛋白的表达及其临床意义

目的:探讨脊柱浆细胞骨髓瘤（plasma cell myeloma,PCM）中骨桥蛋白(osteopontin,OPN)的表达及其与临床病理特征和预后的相关性。方法：选取第二军医大学长征医院19982006年间41例脊柱PCM及14例脊柱良性单纯性骨囊肿手术切除标本;应用免疫组织化学链霉菌抗生物素蛋白过氧化物酶连结（SP）法检测OPN的表达。结果：（1）OPN在脊柱PCM中的阳性表达率为82.93%(34/41) ,而良性骨囊肿中OPN表达均呈阴性 (P<0.01);（2）脊柱PCM中OPN蛋白的表达程度在M蛋白分型和临床分型各组之间差异均有统计学意义（P<0.05）,而与患者轻链分型、病理形态学分级、年龄和性别无显著关联（P>0.05）;（3）OPN表达阳性患者整体生存率明显高于阴性组(P<0.01)。结论：OPN表达阴性脊柱PCM患者的预后可能较差。联合检测OPN和M蛋白分型以及临床分型对脊柱PCM预后判断可能有一定的临床意义。     

Ezrin在乳腺癌发生发展中的表达及意义

目的:探讨Ezrin在乳腺癌发生、发展中的作用,研究其在乳腺癌中的表达及临床意义.方法:应用免疫组化SP法测定Ezrin的表达,所有实验数据录入计算机,用SPSS13.0进行统计学分析.结果:Ezrin异常阳性表达率在乳腺普通导管增生、不典型导管增生、导管内癌、浸润性导管癌中分别为21.4%、25.0%、44.4%、70.3%,差异有显著统计学意义(P＜0.01).比较普通导管增生组(21.4%)与不典型增生组(25.0%),差异无统计学意义(P>0.05).而导管内癌组(44.4%)与浸润性导管癌组(70.3%)间差异有统计学意义(P＜0.05).乳腺增生组(23.1%)与乳腺癌组(64.6%)比较,差异有显著统计学意义(P＜0.01).在浸润性导管癌中,Ezrin高表达与患者年龄无关(P>0.05),与原发肿瘤大小、组织学分级、临床TNM分期、腋淋巴结转移均有关(P＜0.05),同时随着淋巴结转移数目增多,Ezrin异常阳性表达率增高(P＜0.05).结论:Ezrin高表达参与乳腺癌的发生、发展,与原发肿瘤大小、组织学分级、临床TNM分期、腋淋巴结转移等预后指标有关,提示检测Ezrin可作为判定乳腺癌发生、发展及预后的可靠指标.     

Immunohistochemical Evaluation of 95 Bone Marrow Reactive Plasmacytoses

We histologically and immunohistochemically studied 95 bone marrow (BM) reactive plasmacytoses. Ten biopsies from plasma cell myeloma (PCM) patients served as a control group. In addition, we studied 10 monoclonal gammopathy of undetermined significance (MGUS) cases. Histologically, plasmacytosis varied between 5% and 25% with an interstitial pattern of plasma cell (PC) distribution being characteristically displayed. Immunohistochemically, we did not find any CD56/NCAM nor cyclin D1 expression in all biopsies (95 of 95, 100%), not even a weak, doubtful one; PCs were all polyclonal and CD138 positive. On the contrary, myeloma-associated PCs showed monoclonality for κ- or λ- light chain and strong CD56/NCAM immunoreactivity (8 of 10, 80%); four of them were cyclin D1 positive. Osteoblasts exhibited similar CD56/NCAM expression in both groups. Our data confirm the diagnostic utility of CD56/NCAM in the phenotypic characterization of polyclonal plasma cells, suggesting an important role of this particular immunomarker in the BM trephine study of polyclonal versus neoplastic plasmacytic infiltrations.     

CD56+表达对急性单核细胞白血病儿童的临床特征、疗效及预后的影响

目的探讨CD56⁺表达对急性单核细胞白血病(AML-M5)儿童临床特征、疗效及预后的影响。方法对84例14岁以下AML-M5患儿临床资料进行回顾性分析,分析CD56的表达与临床特征、疗效及预后的关系。结果CD56⁺表达率为32.14%,白细胞计数(73.21±12.93)×10⁹/l,高白细胞血症占51.85%,髓外浸润占59.26%;CD56^-表达率为67.86%,白细胞计数(54.21±10.64)×10⁹/l,高白细胞血症占15.79%,髓外浸润占29.82%,比较差异具有统计学意义(P<0.05)。CD56+患儿治疗完全缓解率为62.96%、死亡率为7.41%,CD56^-患儿完全缓解率66.67%、死亡率8.77%,比较差异无统计学意义(P>0.05);CD56⁺达完全缓解的患儿随访期间复发率76.47%、持续缓解率为23.53%,平均生存时间(10.92±4.71)个月,CD56^-患儿复发率28.95%、持续缓解率为71.05%、平均生存时间(15.15±8.12)个月,比较差异具有统计学意义(P<0.05)。结论CD56⁺表达的14岁以下AML-M5患儿高白细胞血症、髓外浸润发生及复发率较高,平均生存时间较短。CD56表达能够为患儿的治疗及预后提供指导信息。     

p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma

Progression of multiple myeloma (MM) from intramedullary to extramedullary sites heralds an aggressive phase of the disease but to the best of our knowledge, biologic factors have not been studied in paired biopsies from medullary and extramedullary sites. In this study, we immunostained paired bone marrow and extramedullary biopsies from 12 cases of MM for p53, CD56 and MIB-1 (proliferative index). In addition, 22 cases of extramedullary plasmacytoma (EMP) without bone marrow involvement were included as a control group. p53 nuclear accumulations were detected in myeloma cells derived from the extramedullary sites in 9 (75%) of the 12 cases, whereas only 1 of (8%) 12 bone marrow myeloma specimens expressed p53 (P = 0.003). p53 expression was also more prevalent in extramedullary sites of MM than EMP (75% vs. 18%, P = 0.003). There was no significant difference in CD56 expression between intramedullary and extramedullary MM (17% vs. 33%, P = 0.64), or between intramedullary MM and EMP (17% vs. 38%, P = 0.25). The MIB-1 proliferation index increased significantly as plasma cells migrated from the bone marrow microenvironment to extramedullary sites (P = 0.0001). Our data indicates that p53 nuclear expression but not CD56 expression, along with increased proliferation index is associated with disease progression from intramedullary to extramedullary sites in MM.     

Primary plasma cell leukaemia: a report of 18 cases

Primary plasma cell leukaemia (P-PCL) is a variant of multiple myeloma (MM) first diagnosed in the leukemic phase, with >2000/mm(3) circulating plasma cells (PCs) and plasmacytosis >20% of the white cell count. We investigated the clinical characteristics, therapy, immunophenotype and prognosis factors of 18 patients. Common features at diagnosis were asthenia (seven patients), renal insufficiency (ten patients), bone pain (seven patients), splenomegaly or hepatomegaly (five patients). Hypercalcemia was present at diagnosis in seven patients and was the most potent poor prognosis factor (P<0.05). Most patients (16 out of 18) were treated with an anthracyclin containing regiment; complete remission was attained in one patient and partial remission in 11 patients while six patients had no response. The median survival time from diagnosis was 7 months (2--12, 95% confidence interval), but response to treatment had favorable predictive value (P<0.05). The PCs were usually positive for mature B-cell markers (PCA-1, CD38). They expressed integrins which may increase their binding to endothelial cells and thus participate in PCL physiopathology by favoring plasmocyte extramedullary spread.     

Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia

The biological significance of CD56 antigen expression in patients with acute promyelocytic leukemia (APL) has been under investigation. We investigated the clinical and biologic features of CD56+APL. In our series, CD56 antigen was positive in 4 of 28 (14%) APL patients. No differences were found regarding age, gender, performance status (PS), initial leukocyte and platelet counts, lactate dehydrogenase (LDH) and fibrinogen (Fbg) levels according to CD56 expression. CD34 antigen was co-expressed in 3 of the 4 patients with CD56+ APL, in contrast to 2 of the 24 patients with CD56- APL (P = .01). Extramedullary relapse occurred in 3 of the 4 patients with CD56+ APL, in contrast to none of the 24 patients with CD56- APL (P = .001). Median remission duration was 4 months in CD56+ APL and was not reached in CD56- APL. The CD56+ population had a shorter remission duration (P < .0001) and disease-free survival (P < .0001). In contrast, no difference was found in overall survival. These results suggested that CD56 expression was associated with the leukemogenetic mutation at the primitive hematopoietic progenitor cell level and extramedullary relapse in APL patients treated with ATRA and chemotherapy.     

Immunohistological diagnosis of plasma cell myeloma based on cytoplasmic kappa/lambda ratio of CD138-positive plasma cells

Abstract For differentiating reactive plasmacytosis from clonal plasma cell neoplasms such as plasma cell myeloma (PCM), it is important to determine the expression of the cytoplasmic light chain accurately. Through retrospective analysis, we studied the cytoplasmic kappa/lambda ratio of CD138-positive plasma cells in bone marrow from 50 patients with PCM and 50 controls by immunohistological analysis. The percentage of cytoplasmic light chain immunoreactive cells out of the total plasma cell population was shown by a novel quantitative image analysis approach using an Aperio ScanScope CS and the Membrane v9 algorithm. PCM cells were distinguished from normal plasma cells by cut-off levels between 0.35 and 5.5, a sensitivity of 100% and a specificity of 98.0%. Detection of the cytoplasmic kappa/lambda ratio of CD138-positive plasma cells could be a useful tool for simple, efficient and accurate diagnosis of PCM.     

Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome

We evaluated the frequency and prognostic significance of extramedullary infiltrates (EMI) at presentation of acute myeloid leukemia (AML) in adult patients. Of 331 cases with de novo AML, 101(30.5%) had extramedullary infiltrates at diagnosis. The extramedullary manifestations included: lymphadenopathy, splenomegaly, hepatomegaly, gingival hypertrophy, skin infiltrates and involvement of central nervous system (CNS). Patients with EMI had a high initial WBC count and a high proportion of M4/M5 morphological variants. The complete remission rate (CR) with induction chemotherapy was lower in patients with EMI (P=0.0077) and their overall survival was also inferior (P=0.0017). Flow cytometric evaluation of the surface antigens expressed by the leukemic blasts for CD34, TdT, HLADR, CD7, CD19 and CD56 found that only CD56 expression was associated with EMI. The association of CD56 expression with lymphadenopathy was statistically significant (P=0.035). Abnormal karyotypes were found in 50.6% of patients with EMI and 49.7% of patients without EMI. Only 11q23 abnormalities were associated with specific sites of EMI; lymphadenopathy (P=0.0111) and gingival hypertrophy (P=0.0016). Our study of adult AML patients demonstrates that EMI at diagnosis is associated with CD56 expression by leukemic blasts, 11q23 karyotypic abnormalities, low complete remission rate and poor overall survival.     

Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone.

The clinical features and response to therapy of 32 Chinese patients with localised plasmacytoma are presented, and a comparison between extramedullary plasmacytoma (EMP) and solitary plasmacytoma of bone (SPB) is made. Twenty-two patients had SPB and ten had EMP, accounting for 9% of all of our plasma cell neoplasms. Both groups had a male predominance with a median age of 54 years for SPB and 63 years for EMP. The common sites of SPB included vertebral bodies (15) and the skull (4). Most EMPs occurred in the oronasopharynx (6) and paranasal sinuses (2). An M-protein was detected in eight patients with SPB and in six with EMP. Seventeen patients with SPB and seven with EMP received radiation therapy, and all achieved initial local control. The pattern of failure in 22 patients with SPB manifested as local recurrence in two, multiple bone metastases without bone marrow plasmacytosis in two, multiple EMP progression in two, and development of multiple myeloma (MM) in one. There were two local recurrences, one further solitary bone involvement and one MM conversion in the EMP group. Local recurrence or dissemination was associated with the appearance of M-protein or an increase in the M-protein level in both groups. There was no significant difference in M-protein status or incidence and patterns of failure between the two groups. Patients with EMP had a more favourable overall survival than those with SPB (P = 0.03). The 5 year disease-free survival rate was 79% for EMP and 58% for SPB (P = 0.53). Patients aged less than 60 years had a better overall survival in the SPB group, but location of tumour, presence of M-protein, radiation dose and chemotherapy did not influence prognosis in either group. Our results indicate that adequate local therapy can result in long-term survival with a low frequency of MM progression for patients with localised plasmacytomas, and both EMP and SPB appear to be similar in terms of frequency and patterns of failure.     

CD56~ 急性髓系白血病血液学特征及其临床意义

目的 :研究CD5 6 急性髓系白血病 (AML)血液学特征及临床意义。方法 :流式细胞计数仪检测白血病细胞分化抗原的表达 ;RT PCR检测EBV mRNA ;电镜及免疫电镜观察超微结构 ;回顾性分析初诊时血液学特点、临床表现及对化疗的反应。结果 :CD5 6表达率为 30 .6 2 %(79 2 5 8) ;CD5 6 AML中未见EBV感染 ;电镜及免疫电镜发现CD5 6 AML细胞核中存在 1— 2团絮状结构 ;CD5 6的表达与年龄、性别、WBC、Hb、BPC、BM中白血病细胞数、CR率及CR期无关 (P值分别为 0 .12 8,0 .877,0 .181,0 .86 6 ,0 .6 2 9,0 .40 7,0 .998,0 .0 96 ) ;与较多的髓外侵润(77.78%对 6 1.11%,P =0 .0 19)、CD34表达 (6 6 .6 7%对 46 .48%,P =0 .0 3)、P170表达 (5 1.79%对 34 .94%,P =0 .0 48)及较短的生存期有关 (中位数 ,11.5个月对 18个月 ;P值 0 .0 478)。结论 :CD5 6 AML是一种特殊类型的白血病 ,预后较差 ,应进一步分型并针对性治疗。     

Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma

Currently, CD133 is one of the best markers to characterize cancer stem cells and Her-1 is reported as an important marker for the prognosis of triple-negative breast cancer. To investigate the relationship between the expression of CD133 and Her-1 and clinicopathology as well as prognosis in triple-negative breast cancer, 67 cases of triple-negative invasive ductal breast carcinoma taken from 422 patients with breast cancer were analyzed by immunohistochemistry and clinicopathology with follow-up. The CD133 and Her-1 were expressed as positive in 43.3% (29/67) and 53.7% (36/67) of patients, respectively. The expression of CD133 corresponded to tumor size (P = 0.022), clinical stage (P = 0.001) and lymphatic metastasis (P = 0.001), but not to age and histological grade. By Kaplan-Meier analysis the expression of CD133 was correlative with overall survival (OS) (log rank = 9.346, P = 0.002) and disease free survival (DFS) (log rank = 38.840, P = 0.0001) time of breast cancer patients. The expression of Her-1 was corresponding to tumor size (P = 0.031), clinical stage (P = 0.005) and lymphatic metastasis (P = 0.002), but not to age and histological grade. By Kaplan-Meier analysis the expression of Her-1 was correlative with overall survival (OS) (log rank = 7.998, P = 0.005) and DFS (log rank = 4.227, P = 0.040) time of patients with cancer. It is concluded that the expression of CD133 and Her-1 may be correlative with prognosis in triple-negative breast cancer.